Evaluation of Serum Mucorales Polymerase Chain Reaction (PCR) for the Diagnosis of Mucormycoses: The MODIMUCOR Prospective Trial
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | Evaluation of Serum Mucorales Polymerase Chain Reaction (PCR) for the Diagnosis of Mucormycoses: The MODIMUCOR Prospective Trial |
Type de publication | Journal Article |
Year of Publication | Submitted |
Auteurs | Millon L, Caillot D, Berceanu A, Bretagne S, Lanternier F, Morio F, Letscher-Bru V, Dalle F, Denis B, Alanio A, Boutoille D, Bougnoux M-E, Botterel F, Chouaki T, Charbonnier A, Ader F, Dupont D, Bellanger A-P, Rocchi S, Scherer E, Gbaguidi-Haore H, Herbrecht R |
Journal | CLINICAL INFECTIOUS DISEASES |
Type of Article | Article; Early Access |
ISSN | 1058-4838 |
Mots-clés | circulating DNA, molecular diagnosis, Mucorales quantitative PCR, mucormycosis |
Résumé | {Background Early diagnosis and prompt initiation of specific antifungal treatment are essential for improving the prognosis of mucormycosis. We aimed to assess the performance of serum Mucorales quantitative polymerase chain reaction (qPCR) for the early diagnosis and follow-up of mucormycosis. Methods We prospectively enrolled 232 patients with suspicion of invasive mold disease, evaluated using standard imaging and mycological procedures. Thirteen additional patients with proven or probable mucormycosis were included to analyze DNA load kinetics. Serum samples were collected twice-a-week for Mucorales qPCR tests targeting the Mucorales genera Lichtheimia, Rhizomucor, and Mucor/Rhizopus. Results The sensitivity was 85.2%, specificity 89.8%, and positive and negative likelihood ratios 8.3 and 0.17, respectively in this prospective study. The first Mucorales qPCR-positive serum was observed a median of 4 days (interquartile range [IQR], 0-9) before sampling of the first mycological or histological positive specimen and a median of one day (IQR, -2 to 6) before the first imaging was performed. Negativity of Mucorales qPCR within seven days after liposomal-amphotericin B initiation was associated with an 85% lower 30-day mortality rate (adjusted hazard ratio = 0 center dot 15, 95% confidence interval [.03-.73] |
DOI | 10.1093/cid/ciab1066 |